Concorde Asset Management LLC Boosts Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Concorde Asset Management LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 21.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 554 shares of the medical equipment provider’s stock after buying an additional 97 shares during the period. Concorde Asset Management LLC’s holdings in Intuitive Surgical were worth $289,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atala Financial Inc purchased a new stake in Intuitive Surgical in the 4th quarter worth approximately $25,000. Hurley Capital LLC bought a new position in shares of Intuitive Surgical in the fourth quarter worth $28,000. Berbice Capital Management LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth $26,000. BankPlus Trust Department bought a new stake in Intuitive Surgical during the fourth quarter valued at $28,000. Finally, Summit Securities Group LLC purchased a new position in Intuitive Surgical during the fourth quarter worth about $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 6.4 %

NASDAQ:ISRG opened at $489.52 on Friday. The firm has a market capitalization of $174.36 billion, a P/E ratio of 76.37, a P/E/G ratio of 5.85 and a beta of 1.55. The company has a fifty day moving average of $534.44 and a 200 day moving average of $532.30. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ISRG shares. Jefferies Financial Group lifted their price target on Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Truist Financial dropped their target price on shares of Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Evercore ISI increased their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Citigroup lifted their price objective on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Finally, Leerink Partners increased their target price on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $611.86.

Insider Buying and Selling at Intuitive Surgical

In related news, VP Fredrik Widman sold 810 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $573.78, for a total value of $464,761.80. Following the sale, the vice president now directly owns 473 shares of the company’s stock, valued at $271,397.94. This trade represents a 63.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Desantis sold 11,545 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total value of $5,763,494.90. Following the transaction, the executive vice president now directly owns 5,224 shares of the company’s stock, valued at $2,607,925.28. The trade was a 68.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,754 shares of company stock worth $17,691,621. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.